NCT00864760View on ClinicalTrials.gov

A Relative Bioavailability Study of Gabapentin 800 mg Tablets Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 1999

Primary Completion Date

June 30, 1999

Study Completion Date

June 30, 1999

Conditions
Healthy
Interventions
DRUG

Gabapentin 800 mg tablets, single dose (1 tablet)

A: Experimental Subjects received Purepac formulated products under fasting conditions

DRUG

NEURONTIN® 400 mg capsules, single dose (2 capsules)

B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions

Trial Locations (1)

58102

PRACS Institute, Ltd., Fargo

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
lead

Actavis Inc.

INDUSTRY

NCT00864760 - A Relative Bioavailability Study of Gabapentin 800 mg Tablets Under Fasting Conditions | Biotech Hunter | Biotech Hunter